The biologics manufacturing industry has been optimized for producing large-scale therapeutic batches that consume dedicated manufacturing suites and guarantee premium budgets. However, recent years have seen a trend towards more products needing small scale batches for clinical trials, orphan indications, and more. Despite this trend, the industry has struggled to offer reasonable pricing and timelines, and often these small scale batches are overlooked for larger projects that can bring in higher revenue.
Single-use, fully automated bioreactors can significantly reduce both capital and operating costs. A cost analysis using single-use, perfusion AcuSyst bioreactors and found a 15-30% reduction in manufacturing costs compared with stirred tank bioreactors.